Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SRPT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Golodirsen FDA approved Dec 2019 · Vyondys 53 |
Duchenne Muscular Dystrophy | Phase 4 · NCT04708314 | Terminated |
| Casimersen FDA approved Feb 2021 · Amondys 45 |
Duchenne Muscular Dystrophy | Phase 3 · NCT02500381 | Completed |
| Eteplirsen FDA approved Sep 2016 · Exondys 51 |
Muscular Dystrophy, Duchenne | Phase 3 · NCT03992430 | Completed |
| Antibiotic | Duchenne Muscular Dystrophy | Phase 4 · NCT07542314 | Recruiting |
| Glucocorticoids | Duchenne Muscular Dystrophy | Phase 4 · NCT07542314 | Recruiting |
| Delandistrogene Moxeparvovec-Rokl | Duchenne Muscular Dystrophy | Phase 4 · NCT07542314 | Recruiting |
| Bidridistrogene Xeboparvovec | Limb-girdle Muscular Dystrophy | Phase 3 · NCT06246513 | Active not recruiting |
| Glucocorticoid | Limb-girdle Muscular Dystrophy | Phase 3 · NCT06246513 | Active not recruiting |
| Corticosteroid | Muscular Dystrophies, Limb-Girdle | Phase 3 · NCT06952686 | Withdrawn |
| SRP-9005 | Muscular Dystrophies, Limb-Girdle | Phase 3 · NCT06952686 | Withdrawn |
| AVI-4658 (Eteplirsen) | Duchenne Muscular Dystrophy | Phase 1/2 · NCT00159250 | Completed |
| SRP-1001 for Injection | Muscular Dystrophy, Facioscapulohumeral | Phase 1/2 · NCT06131983 | Enrolling by invitation |
| SRP-1003 IV Infusion | Myotonic Dystrophy 1 | Phase 1/2 · NCT06138743 | Enrolling by invitation |
| SRP-1003 SC Injection | Myotonic Dystrophy 1 | Phase 1/2 · NCT06138743 | Enrolling by invitation |
| Vesleteplirsen | Muscular Dystrophy, Duchenne | Phase 1/2 · NCT03675126 | Terminated |
| rAAVrh74.MHCK7.DYSF.DV | Dysferlinopathy | Phase 1 · NCT02710500 | Completed |
Also used in these trials (approved or third-party drugs, not SRPT's own candidates): Sirolimus.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SRPT holds $878.8M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SRPT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 16,642,620 | 15.52% | 2026-06-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 8,499,421 | 7.93% | 2026-06-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 7,412,275 | 6.91% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,369,116 | 5.01% | 2026-03-31 |
| Richard Barry Director |
Insider | 3,233,542 | 3.02% | 2026-06-04 |
| Douglas S Ingram Chief Executive Officer, Director |
Insider | 929,391 | 0.87% | 2025-12-07 |
| Michael Severino Chief Executive Officer, Director · +2.22M options |
Insider | 756,104 | 0.71% | 2026-07-28 |
| Michael Andrew Chambers Director |
Insider | 504,027 | 0.47% | 2026-06-04 |
| M Kathleen Behrens Director |
Insider | 224,357 | 0.21% | 2026-06-04 |
| Louise Rodino-Klapac President, R&D and Tech Ops |
Insider | 203,900 | 0.19% | 2026-09-04 |
| Ian Michael Estepan Chief Operating Officer |
Insider | 177,184 | 0.17% | 2026-09-04 |
| Ryan Ho-Yan Wong Chief Financial Officer |
Insider | 121,792 | 0.11% | 2026-09-04 |
Share count 107,235,848 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SRPT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →